Generate Biomedicines
Generate Biomedicines raises $370M Series C at $2B valuation
Generate Biomedicines: Series C Funding Round
Generate Biomedicines has successfully raised $370M in Series C funding, reaching a valuation of $2B.
Company Overview
Generative biology AI drug discovery
Funding Details
The Series C round was led by Flagship Pioneering, with participation from T. Rowe Price, Fidelity, NVIDIA, Alaska Permanent Fund.
Company Information
- Headquarters: 1 Main Street, Cambridge, MA 02142
- Founded: 2018
- Employees: 200+
- Category: Biotech
Investment
Generate Biomedicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in Series C
- T. Rowe Price: Verified investor in Series C
- Fidelity: Verified investor in Series C
- NVIDIA: Verified investor in Series C
- Alaska Permanent Fund: Verified investor in Series C
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free